Mesoblast Limited (NASDAQ:MESO - Get Free Report) shares traded up 9.4% during trading on Tuesday . The company traded as high as $6.10 and last traded at $6.05. 86,065 shares were traded during trading, a decline of 95% from the average session volume of 1,830,111 shares. The stock had previously closed at $5.53.
Analyst Ratings Changes
Several brokerages have recently issued reports on MESO. Cantor Fitzgerald reissued an "overweight" rating on shares of Mesoblast in a report on Friday, January 12th. StockNews.com lowered Mesoblast from a "hold" rating to a "sell" rating in a research note on Tuesday, April 2nd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $13.67.
Get Our Latest Analysis on Mesoblast
Mesoblast Price Performance
The business has a 50 day simple moving average of $3.46 and a 200 day simple moving average of $2.64. The company has a market capitalization of $684.42 million, a price-to-earnings ratio of -5.36 and a beta of 3.59.
Hedge Funds Weigh In On Mesoblast
A hedge fund recently bought a new stake in Mesoblast stock. Prosperity Wealth Management Inc. acquired a new position in shares of Mesoblast Limited (NASDAQ:MESO - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 64,150 shares of the company's stock, valued at approximately $79,000. Institutional investors and hedge funds own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Recommended Stories
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
